Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New Methods for Evaluating Preventive Migraine Treatment
NCT07071506Recruiting
- Sponsor
- Aarhus University
- Start
- Jun 2025
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of fremanezumab in chronic migraine (2 arms), sponsored by Aarhus University. Primary endpoints: Mean change in headache intensity at 8 months, Mean change in moderate/severe headache days at 8 months and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT07071506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071506.